CryoLife ends Medafor acquisition bid
This article was originally published in The Gray Sheet
Executive Summary
Developer of human-tissue-based products ends its bid to acquire privately held surgical hemostat maker Medafor for $2 per share, citing Medafor's reluctance to enter into a purchase agreement and frustration with a recent Medafor deal with component supplier Magle Life Sciences, which CryoLife believes has caused "significant dilution" in Medafor shareholder value. Medafor announced on March 18 that it would treat as terminated the exclusive distribution agreement that it has with CryoLife, citing CryoLife's "failure to provide adequate assurance that it would properly perform its obligations" under the deal. CryoLife remains Medafor's largest shareholder (1"The Gray Sheet" Jan. 18, 2010)
You may also be interested in...
CryoLife Takes Step To Wrest Control Of Reluctant Partner Medafor
CryoLife's purchase of an 8% equity stake in privately held surgical hemostat maker Medafor on Jan. 13 could be the first step of a hostile takeover
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.